Conference Coverage

No benefit seen with radiotherapy in borderline resectable pancreatic cancer


 

Further investigation needed

The paper’s discussant, Rebecca A. Snyder, MD, MPH, of the Brody School of Medicine, East Carolina University, Greenville, N.C., emphasized that this study was not designed or powered to directly compare chemotherapy alone with chemotherapy plus radiotherapy in the neoadjuvant setting.

She noted that it is surprising that the radiotherapy arm was closed early. She said the reasons for this remain unclear, although a few possible reasons can be speculated.

“Based on multiple studies in both the adjuvant and neoadjuvant setting, including the Alliance [A021501] trial presented today, there is no convincing randomized data that radiation therapy prolongs survival in any population of unselected patients with pancreatic cancer,” said Dr. Snyder.

“Certainly, follow-up questions still remain, specifically regarding the role for non-SBRT radiation in the preoperative setting, which may be answered by the ongoing PREOPANC-2 and PRODIGE 44 trials,” she said.

She added that the “addition of SBRT in the preoperative setting does not appear to be justified.”

The role of radiotherapy for subsets of patients remains unknown, and future investigation should focus on patient-centered endpoints, such as symptomatic local control rates, Dr. Snyder concluded.

The study was funded by the National Institutes of Health. Dr. Katz has had a consulting or advisory role for AbbVie and Alcresta Therapeutics. Dr. Snyder has disclosed no relevant financial relationships.

The Gastrointestinal Cancers Symposium is sponsored by the American Gastroenterological Association, the American Society for Clinical Oncology, the American Society for Radiation Oncology, and the Society of Surgical Oncology.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Younger adults present with more advanced esophageal adenocarcinoma
MDedge Hematology and Oncology
CRC risk in young adults: Not as high as previously reported
MDedge Hematology and Oncology
Differences in right vs. left colon in Black vs. White individuals
MDedge Hematology and Oncology
Study reveals how aspirin may inhibit colorectal cancer
MDedge Hematology and Oncology
Endoscopic CRC resection carries recurrence, mortality risks
MDedge Hematology and Oncology
U.S. cancer death rates drop for second year in a row
MDedge Hematology and Oncology
Color-imaging endoscopy improves detection of upper GI cancer
MDedge Hematology and Oncology
Bemarituzumab FIGHTs gastric/GEJ cancers, improving survival
MDedge Hematology and Oncology
Gut microbiome may predict nivolumab efficacy in gastric cancer
MDedge Hematology and Oncology
Better survival with S-1 plus docetaxel in stage III gastric cancer
MDedge Hematology and Oncology